Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson's disease.
about
Preclinical pharmacology and pharmacokinetics of CERC-301, a GluN2B-selective N-methyl-D-aspartate receptor antagonistRole of cues and contexts on drug-seeking behaviourTargeting β-arrestin2 in the treatment of L-DOPA-induced dyskinesia in Parkinson's disease.Unprecedented therapeutic potential with a combination of A2A/NR2B receptor antagonists as observed in the 6-OHDA lesioned rat model of Parkinson's diseaseBrain morphometry and the neurobiology of levodopa-induced dyskinesias: current knowledge and future potential for translational pre-clinical neuroimaging studies.Multireceptor fingerprints in progressive supranuclear palsy.Compound Formula Rehmannia alleviates levodopa-induced dyskinesia in Parkinson's disease.Role for the nicotinic cholinergic system in movement disorders; therapeutic implications.The α7 nicotinic receptor agonist ABT-107 decreases L-Dopa-induced dyskinesias in parkinsonian monkeysNew treatments for the motor symptoms of Parkinson's disease.Location-dependent signaling of the group 1 metabotropic glutamate receptor mGlu5.α7 nicotinic receptor agonists reduce levodopa-induced dyskinesias with severe nigrostriatal damage.Optogenetic activation of striatal cholinergic interneurons regulates L-dopa-induced dyskinesiasNew drug classes for the treatment of partial onset epilepsy: focus on perampanel.Glutamate signaling in benign and malignant disorders: current status, future perspectives, and therapeutic implications.Treatment of Parkinson's disease: what's in the non-dopaminergic pipeline?Repetitive transcranial magnetic stimulation (rTMS) improves behavioral and biochemical deficits in levodopa-induced dyskinetic rats model.ABT-089 and ABT-894 reduce levodopa-induced dyskinesias in a monkey model of Parkinson's disease.Non-dopaminergic treatments for motor control in Parkinson's disease.A further update on the role of excitotoxicity in the pathogenesis of Parkinson's disease.Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease.Molecular imaging of levodopa-induced dyskinesias.Antiparkinsonian effects of the "Radiprodil and Tozadenant" combination in MPTP-treated marmosets.Current Nondopaminergic Therapeutic Options for Motor Symptoms of Parkinson's Disease.mGlu5, Dopamine D2 and Adenosine A2A Receptors in L-DOPA-induced Dyskinesias.Design, synthesis, and structure-activity relationship of a novel series of GluN2C-selective potentiators.Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia.Nondopaminergic treatments for Parkinson's disease: current and future prospects.The effects of the β-lactam antibiotic, ceftriaxone, on forepaw stepping and L-DOPA-induced dyskinesia in a rodent model of Parkinson's disease.Metformin Inhibits the Development of L-DOPA-Induced Dyskinesia in a Murine Model of Parkinson's Disease.Targeting metabotropic glutamate receptors as a new strategy against levodopa-induced dyskinesia in Parkinson's disease?Amantadine and the Risk of Dyskinesia in Patients with Early Parkinson's Disease: An Open-Label, Pragmatic Trial.NMDA antagonists for treating the non-motor symptoms in Parkinson's disease.
P2860
Q26750021-B35ACA06-4DC5-4FAE-99AB-6F78EF777352Q26825476-B827FD92-E533-49D2-96E4-A8F60BDC8492Q27324174-AA834BF8-1DA2-4885-85B7-C0764E197C72Q28542729-D12A2897-7EA2-4CA4-967F-7744A25678E1Q30833645-4A942992-2560-4266-8F23-B73C835A6AA2Q33568690-F5C8DE70-9371-40DB-B349-D244E3632C9DQ34095853-720E4F5B-0758-4693-9572-E82004E9B55FQ34112026-5D1022C6-B5B4-452E-B587-B1D0691840E0Q34186299-9938D19D-F145-4C8E-8CD8-8D718960C6DDQ34443682-5741841E-CEE8-4B75-936A-020F6EC2CA89Q34573953-16FB8614-D66E-459A-AA57-271699D0FFC8Q36469995-331750C7-68D2-4F00-BB98-D877DAD7622DQ36880148-E06F17AF-5CFB-411A-826D-6AA6D5FB370EQ37014640-040AA81C-7350-4479-937B-8521E95583AAQ37121338-E648A816-6DB4-4FFA-9A63-C798EABE238EQ37506507-E03F02D0-85F8-460D-87FD-EB0389642E89Q37644775-09E77219-3B7B-43F6-9FA2-D213E72A55B2Q37708588-0D3D5D91-E7DB-4410-B7A3-260EFB8728A6Q38126817-43C9D2F1-015E-43F8-906C-74A4C1BF84E3Q38174986-35C24250-2B2B-4A89-ACAD-F1F26E86AD22Q38262418-EE4E5A72-033F-4F97-93AA-C1803442B03DQ38355582-7EEEEEAA-38B1-4846-A627-6EBC20F5DB7BQ38602173-531F11BE-55ED-4200-8AA5-05A00865D15EQ38658203-2D9F12A4-84C0-47B2-99E5-8E971CB95EA2Q38660240-8688F487-DE1A-4E4A-A74F-C4A804F9D4A3Q38705814-7C062329-F54D-40E0-BDE4-E7F8E7D762E9Q38811387-197AC99B-A422-43D5-B986-5931E22BB852Q38845546-89A5D551-90B0-425D-A288-AFDF66BE6EA7Q46332293-1406B842-A0FE-4DEB-9C33-72D51BBE2190Q48177380-E7042D51-6640-4021-8818-DF5065EEADD7Q51750611-85674F8F-3199-4852-AB37-33F6CA98D690Q55312669-36483F76-8FFF-472C-8DA6-1DE83A45AD19Q55474333-10B6A9CC-38EB-4819-A88A-56D194C2F2CB
P2860
Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson's disease.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Targeting glutamate receptors ...... ated with Parkinson's disease.
@en
type
label
Targeting glutamate receptors ...... ated with Parkinson's disease.
@en
prefLabel
Targeting glutamate receptors ...... ated with Parkinson's disease.
@en
P2860
P921
P1433
P1476
Targeting glutamate receptors ...... ated with Parkinson's disease.
@en
P2093
Susan Duty
P2860
P2888
P304
P356
10.1007/S40263-012-0016-Z
P577
2012-12-01T00:00:00Z